Omega 3 pentaenoic acid + icosapent ethyl

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hypertriglyceridemia

Conditions

Hypertriglyceridemia

Trial Timeline

Jun 3, 2020 → Jan 18, 2021

NCT ID

NCT04177680

About Omega 3 pentaenoic acid + icosapent ethyl

Omega 3 pentaenoic acid + icosapent ethyl is a phase 2 stage product being developed by Matinas Biopharma for Hypertriglyceridemia. The current trial status is completed. This product is registered under clinical trial identifier NCT04177680. Target conditions include Hypertriglyceridemia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04177680	Phase 2	Completed	Jun 3, 2020	Jan 18, 2021	Hypertriglyceridemia

Competing Products

20 competing products in Hypertriglyceridemia

See all competitors

Product	Company	Stage	Hype Score
LY3875383 + Placebo	Eli Lilly	Phase 1	33
ZYH7 + ZYH7 + ZYH7 + Fenofibrate	Zydus Lifesciences	Phase 2	52
Solbinsiran + Placebo	Eli Lilly	Phase 2	52
Placebo + Ethyl Icosapentate	Sumitomo Pharma	Phase 3	77
Omega-3-Acid Ethyl Esters 90 Soft Capsules + Corn Oil	Jiangsu Hengrui Medicine	Phase 3	77
warfarin + omefas + omega-3-acid ethyl esters	AstraZeneca	Phase 1	33
rosuvastatin	AstraZeneca	Approved	85
Simvastatin + acetylsalicylic acid (ASA) + omefas	AstraZeneca	Phase 1	33
Olive oil, 4g + omega-3-carboxylic acids, 2g + omega-3-carboxylic acids, 4g	AstraZeneca	Phase 3	77
Epanova (4 g) and Lovaza (4 g) + Lovaza (4 g) and Epanova (4 g)	AstraZeneca	Phase 2	52
rosuvastatin 40 mg tablet + Epanova™ QD (2 x 1 g capsules) + Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose + Multiple (20) oral doses of 2 g Vascepa® every 12 hours	AstraZeneca	Phase 1	33
placebo + omefas + omefas + omefas	AstraZeneca	Phase 2/3	65
Epanova + Lovaza	AstraZeneca	Phase 1	33
Epanova + Olive Oil	AstraZeneca	Phase 3	77
AZD0585 + AZD0585 placebo	AstraZeneca	Phase 3	77
ABT-143 + simvastatin	AstraZeneca	Phase 3	77
Maraviroc	Pfizer	Phase 1	32
torcetrapib/atorvastatin + atorvastatin	Pfizer	Phase 3	76
Icosapent (MND-2119) + Icosapent (EPADEL CAPSULES 300)	Mochida Pharmaceutical	Phase 3	76
Icosapent	Mochida Pharmaceutical	Phase 3	76

Other Products from Matinas Biopharma

Placebo + MAT9001 (omega-3 pentaenoic acid)Phase 3

MAT2203 + Amphotericin BPhase 3

Oral Encochleated Amphotericin B (CAMB)Phase 2

Amphotericin BPhase 2

Oral Encochleated Amphotericin B (CAMB) + Oral Encochleated Amphotericin B (CAMB)Phase 2